SCHEMBL103763

SCHEMBL103763

CC(C)CCOc1ccccc1N=C=O

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.50
IDO1 P14902 1/20 0.42
CYP3A4 P08684 2/20 0.41
TLR8 Q9NR97 1/20 0.40
MCHR1 Q99705 1/20 0.40
POLB P06746 1/20 0.40
ALDH1A1 P00352 3/20 0.38
TDP1 Q9NUW8 2/20 0.38
HPGD P15428 1/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MBTPS1 Q14703 1/20 0.37
KDM4E B2RXH2 2/20 0.37
HSD17B10 Q99714 1/20 0.37
MAPK1 P28482 1/20 0.36
XDH P47989 1/20 0.36
EPHX2 P34913 1/20 0.35
PPIA P62937 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10341850 0.85 CYP3A4 (0.45) HTTCYP3A4POLBALDH1A1TDP1
SCHEMBL9622718 0.84 CYP3A4 (0.43) CYP3A4TLR8POLBALDH1A1TDP1
SCHEMBL11756186 0.82 CYP3A4 (0.44) HTTCYP3A4TLR8MCHR1ALDH1A1
SCHEMBL30631633 0.82 CYP3A4 (0.44) HTTCYP3A4TLR8MCHR1ALDH1A1
SCHEMBL5441835 0.79 HTR7 (0.54) CYP3A4ALDH1A1SMN1; SMN2KDM4E
SCHEMBL6539807 0.79 HTT (0.54) HTTIDO1TLR8MCHR1POLB
SCHEMBL1021154 0.78 CYP3A4 (0.47) HTTCYP3A4ALDH1A1TDP1HPGD
SCHEMBL30075523 0.78 CYP3A4 (0.47) HTTCYP3A4ALDH1A1TDP1HPGD
SCHEMBL28182396 0.78 LMNA (0.50) CYP3A4TLR8MCHR1ALDH1A1MAPT
SCHEMBL28042659 0.78 LMNA (0.50) CYP3A4TLR8MCHR1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120071475-A1 UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2012-03-22 US disclosed
US-20120071475-A1 UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2012-03-22 US disclosed
US-20120071475-A1 UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2012-03-22 US disclosed
EP-2426135-A1 UREA DERIVATIVE HAVING PI3K INHIBITORY ACTIVITY Shionogi&Co., Ltd. (JP) 2012-03-07 EP disclosed
EP-2426135-A1 UREA DERIVATIVE HAVING PI3K INHIBITORY ACTIVITY Shionogi&Co., Ltd. (JP) 2012-03-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071475-A1 UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY MTOR, STAT3, SLC14A1 HTT 2761/4885IDO1 2145/4885CYP3A4 4200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.